Consensus NeueHealth, Inc.

Equities

NEUE

US10920V4041

Market Closed - Nyse Other stock markets 04:10:00 2024-04-26 pm EDT			5-day change	1st Jan Change
6.11 ^USD	-3.54%		+4.98%	-19.92%

Apr. 10	NeueHealth Amends Credit Facility to Raise Loan Commitment by $30 Million, Plans to Issue Warrants	MT
Apr. 09	NeueHealth, Inc. Enters into an Incremental Amendment to its Credit Facility with New Enterprise Associates	CI

Evolution of the average Target Price on NeueHealth, Inc.

Price target over the last 5 years

History of analyst recommendation changes

1907bacae2844c.bTLpoRPONGu6FjfkIxT9cfv_ivkmmJ8roVyZ45QuMX4.GmeF73uLThrtUWegTHfLNIObxLUQ3bJn8DCrhtF_aUo7ZYH7Y7hXMetUfg~089b5db436f2c499bb19bb8b4298aa4c

Analyst Recommendations on NeueHealth, Inc.

RBC Raises Price Target on NeueHealth to $8 From $7 on Improving Liquidity, Keeps Sector Perform Rating	Mar. 13	MT
RBC Lifts PT on Bright Health Group to $16 From $13 After 'Solid' Results From Continuing Operations, Notes Easing Liquidity Concerns; Sector Perform Kept	23-08-14	MT
Nephron Research Upgrades Bright Health to Buy From Hold, Raises Price Target to $85 From $27	23-06-30	MT
Barclays Downgrades Bright Health Group to Underweight From Overweight	23-06-15	MT
RBC Slashes Price Target on Bright Health Group to $13 From $80, Cites Ongoing Liquidity Concerns, Keeps Sector Perform Rating	23-05-30	MT
Morgan Stanley Adjusts Price Target on Bright Health to $160 From $2, Maintains Underweight Rating	23-05-19	MT
Goldman Sachs Downgrades Bright Health Group to Sell From Neutral With $0.50 Price Target	22-12-13	MT
Citigroup Adjusts Bright Health Group's Price Target to $1.20 From $2.25, Keeps Neutral Rating	22-11-16	MT
JPMorgan Downgrades Bright Health Group to Underweight From Neutral	22-10-12	MT
Piper Sandler Adjusts Price Target on Bright Health Group to $3 From $5, Reiterates Overweight Rating	22-08-11	MT
BofA Securities Adjusts Bright Health Group Price Target to $1 From $1.50, Maintains Underperform Rating	22-06-15	MT
BofA Securities Assess Risks to Managed Care Sector Amid Shifting Regulatory Environment, Market Disruption	22-05-26	MT
JPMorgan Downgrades Bright Health Group to Neutral From Overweight; Price Target is $2	22-03-29	MT
Bright Health Group Downgraded to Sector Perform From Outperform by RBC, Price Target Slashed to $3 From $9 After Q4 Miss	22-03-04	MT
Barclays Adjusts Bright Health Group's Price Target to $4 From $5.50, Reiterates Overweight Rating	22-03-03	MT
Goldman Sachs Adjusts Bright Health Group Price Target to $3.50 From $5, Maintains Neutral Rating	22-03-03	MT
Cowen & Co Adjusts Bright Health Group Price Target to $3 From $6, Maintains Market Perform Rating	22-03-03	MT
BofA Securities Downgrades Bright Health Group to Underperform From Buy, Adjusts Price Target to $2.50 From $6	22-03-03	MT
Piper Sandler Adjusts Price Target on Bright Health Group to $5 From $10, Reiterates Overweight Rating	22-03-03	MT
Barclays Lowers Price Target for Bright Health Group to $5.50 From $9, Maintains Overweight Rating	22-01-07	MT
Morgan Stanley Downgrades Bright Health Group to Underweight from Equalweight, Adjusts Price Target to $4 from $5	21-12-16	MT
Goldman Sachs Reinstates Bright Health Group at Neutral With $5 Price Target	21-12-14	MT
JPMorgan Upgrades Bright Health Group to Overweight From Neutral; Price Target is $6	21-12-10	MT
RBC Slashes Price Target on Bright Health Group to $9 From $22 After Wider-Than-Expected Q3 Loss; Outperform Kept	21-11-12	MT
Morgan Stanley Cuts Bright Health Group to Equal-Weight From Overweight, Price Target to $5 From $13	21-11-12	MT